| 000 | 01571 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513074531.0 | ||
| 264 | 0 | _c19930209 | |
| 008 | 199302s 0 0 eng d | ||
| 022 | _a0041-1337 | ||
| 024 | 7 |
_a10.1097/00007890-199301000-00021 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMacdonald, P S | |
| 245 | 0 | 0 |
_aA prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3. _h[electronic resource] |
| 260 |
_bTransplantation _cJan 1993 |
||
| 300 |
_a110-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAntilymphocyte Serum _xadverse effects |
| 650 | 0 | 4 |
_aAzathioprine _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclosporine _xadministration & dosage |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGraft Rejection _xmortality |
| 650 | 0 | 4 | _aHeart Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLength of Stay |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuromonab-CD3 _xadverse effects |
| 650 | 0 | 4 |
_aPrednisolone _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aT-Lymphocytes _ximmunology |
| 700 | 1 | _aMundy, J | |
| 700 | 1 | _aKeogh, A M | |
| 700 | 1 | _aChang, V P | |
| 700 | 1 | _aSpratt, P M | |
| 773 | 0 |
_tTransplantation _gvol. 55 _gno. 1 _gp. 110-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00007890-199301000-00021 _zAvailable from publisher's website |
| 999 |
_c8379782 _d8379782 |
||